Home / People / Karl Mutter, LL.M.
Portrait of Karl Mutter, LL.M.

Karl Mutter, LL.M.


CMS Rodríguez-Azuero
Calle 75 No.​ 3-53
Languages Spanish, English

Karl is Partner and leads the Intellectual Property and Life Sciences & Healthcare areas. He has 18 years of experience advising clients in protection of trademark rights, patents, industrial models and designs, plant breeder's rights, copyrights and management trademarks, patents and health registrations portfolios at a national and international level. Furthermore, he has extensive experience in IP due diligence processes for the purposes of internal control and mergers and acquisitions of companies. It has also carried out processes to claim rights for infringement by third parties.

Karl has more than 12 of experience assisting clients with all their needs in connection to life sciences & healthcare law. This includes advice for products such as foodstuffs, alcoholic beverages, cosmetics, dietary supplements, medical devices and equipment, and pharma products; in everything related to market approvals, and issues related to labelling, functional claims, and product advertising.

Professional Experience

  • 2018-present – Partner, CMS Rodríguez-Azuero, Bogotá, Colombia
  • 2010-2018 – Founder and Managing Partner, Mutter & Asociados, Bogotá, Colombia
  • 2006-2010 – Practice Director, Cavelier Abogados, Bogotá, Colombia.
  • 2006-2010 – Cavelier Abogdos, Senior Associate, Bogotá, Colombia
  • 2004 – Consultant and Associate Researcher, Academy of the World Intellectual Property Organization-WIPO, Geneva, Switzerland
  • 2000-2003 – Senior Associate, Cavelier Abogados, Bogotá, Colombia


  • Karl Mutter, Chambers Latin America 2021, Lifesciences (Band 4)
  • Area recognition: Chambers Latin America 2021, Lifesciences (Band 3)
  • Area recognition: Legal 500 Latin America 2021, Intellectual Property (Tier 4)
  • Area recognition: Legal 500 Latin America 2021, Lifesciences (Tier 3)
  • Karl Mutter, Legal 500 Latin America 2021, Lifesciences (Leading Lawyer)
  • Karl Mutter, Legal 500 Latin America 2021, Lifesciences and Intellectual Property (Recommended Lawyer)
  • Area recognition: Leaders League 2020, IP litigation (Highly Recommended)
  • Area recognition: Leaders League 2020, Trademark prosecution (Highly Recommended)
  • Area recognition: Leaders League 2020, Lifesciences Regulatory (Recommended)
more less


  • 2006 – Scholarship recipient, Franklin Pierce Law Center, -FPLC-, Institute of Summer in Intellectual Property -IPSI, Concord, USA
  • 2004 – Master of Laws (LL.M. Degree Cum Laude) with Specialization in Intellectual Property, Katholieke Universiteit Leuven, Leuven, Belgium
  • 2002 – Summer Course on Intellectual Property, Scholarship recipient, World Property Organization Intellectual-WIPO, Geneva, Switzerland
  • 2000 – Lawyer, University of the Andes, Bogota, Colombia
more less


Trans­fer of IP rights in Colom­bia
Pat­ents: As­sign­ment 1. How may a pat­ent be as­signed (by law and/or trans­ac­tion) and is it re­quired to re­cord the as­sign­ment in the na­tion­al pat­ent re­gister to be­come ef­fect­ive?  Pat­ent as­sign­ments...
Plastics and pack­aging laws in Colom­bia
1. What is the gen­er­al le­gis­lat­ive frame­work reg­u­lat­ing pack­aging and plastic waste in your jur­is­dic­tion? The reg­u­lat­ory frame­work for pack­aging and plastics can be found in:lower-ro­man­Decree 2811 of...
Can­nabis law and le­gis­la­tion in Colom­bia
Med­ic­al use Grow­ing, selling and im­port­ing can­nabis for med­ic­al use is al­lowed in Colom­bia.There are sev­er­al au­thor­it­ies in­volved in the au­thor­isa­tion pro­cesses. The ICA (the Colom­bi­an Agency for Ag­ri­cul­tur­al...
Phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising in...
1. Which laws are ap­plic­able re­gard­ing ad­vert­ising of medi­cines and med­ic­al devices? 1.1 Medi­cines De­cree 677/1995Res­ol­u­tion 4536/1996Res­ol­u­tion 4320/2004 1.2 Med­ic­al devices De­cree 4725/2005 2. Are...
¿Worms for your lunch­box?
We could ar­gue (without get­ting too philo­soph­ic­al), that our food to some ex­tent is a cul­tur­al con­struc­tion. We are not go­ing to talk about this in this art­icle, but it is an in­ter­est­ing de­bate to de­term­ine...
Brand Pro­tec­tion in New Me­dia, the case of Hasht­ags
Trade­marks make it pos­sible to identi­fy the busi­ness ori­gin of products on the mar­ket and for many this simply means a logo or a name af­fixed to a product. However, the concept of trade­marks is al­most...
Face Masks as Med­ic­al Devices, To Be or not To Be
It has been a dif­fi­cult year. An atyp­ic­al year in which with­in all the chal­lenges we en­counter we have to ad­opt new habits. One of those, that most af­fects our daily lives is hav­ing to wear face masks...
Ruth Bader Gins­bur­g's Copy­right Leg­acy
Not long ago in this same space we ana­lyzed the case of the book­ing.com trade­mark re­gis­tra­tion, which, as gran­ted, es­tab­lished an im­port­ant pre­ced­ent re­gard­ing the re­gis­trab­il­ity of trade­marks re­lated...
Gen­er­ic Trade­marks on the In­ter­net - The book­ing.com case
When a com­pany is in­ter­ested in po­s­i­tion­ing a brand, the first thing it should eval­u­ate is if the trade­mark can really ob­tain pro­tec­tion, that is, to have ex­clus­ive rights on the use of this name in the...
The Lat­in Amer­ic­an Gen­er­al Coun­sel
The first CMS Gen­er­al Coun­sel re­port in the Lat­in Amer­ica re­gion, “The Lat­in Amer­ic­an GC: Rising to the chal­lenge”, ex­plores the de­vel­op­ment of the Gen­er­al Coun­sel role and how the world in which...
Pro­ced­ures of San­it­ary Reg­u­la­tion for “Non-In­dis­pens­able” Products in times...
In these strange times, the role of health au­thor­it­ies in re­gard to product man­age­ment is es­sen­tial to prop­erly handle and ward off the crisis. In Colom­bia, the au­thor­ity in charge of grant­ing au­thor­iz­a­tion...
Colom­bi­a's Health Au­thor­ity ad­apts to COV­ID Health Emer­gency: On­line pro­ced­ures,...
This whole text is cur­rently not avail­able in Eng­lish be­cause of its loc­al fo­cus. It refers to IN­VIMA de­clar­ing the sus­pen­sion of pro­ced­ur­al dead­lines for cer­tain pro­ced­ures con­sidered non vi­tal, the...